Ozempic and dental implant healing

Dental implants succeed when the surrounding bone grows into the surface of the implant, a process called osseointegration. Diabetes matters here because poorly controlled hyperglycemia impairs the immune response, reduces collagen production, and increases the risk of post-surgical infection. The ADA notes that in patients with poorly controlled diabetes, implant placement may have an unpredictable prognosis, delayed osseointegration, and higher risk of failure — while implants are generally reliable in patients with properly controlled diabetes. The ADA does not set a universal HbA1c cutoff; individual planning considers overall glycemic control.

Semaglutide itself has not been established as a direct cause of implant failure. If you take it for type 2 diabetes, its role is to help release insulin and slow gastric emptying, which supports long-term glucose control. Human evidence on medication-specific effects of GLP-1 therapy on jaw bone and osseointegration remains limited, and no strong claim in either direction is currently warranted at this level of evidence.

The most common practical issue we see on semaglutide is not the medication itself but its GI side effects: nausea, vomiting, and reduced appetite. After implant surgery you usually need to eat soft, nutritious meals for several days; if food is unappealing, that recovery window gets harder regardless of why you take the medication.